Technical Analysis for SCLP - Scancell Holdings Plc

Grade Last Price % Change Price Change
C 22.75 1.11% 0.25
SCLP closed up 1.11 percent on Friday, April 16, 2021, on 20 percent of normal volume. It was able to find support at its 50 day moving average. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical SCLP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Support Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish 1.11%
Bollinger Band Squeeze Range Contraction 1.11%
Older End-of-Day Signals for SCLP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Scancell Holdings Plc Description

Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.


Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Biotechnology Medicine Clinic Pipe Cancer Branches Of Biology Medical Specialties Therapy Clinical Trial Biopharmaceutical Therapies Immunology Antibody Immune System Tumor Antibodies Vaccine Immunotherapy Lung Cancer Monoclonal Antibodies Cancer Therapeutics Treatment Of Cancer

Is SCLP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 29.0
52 Week Low 4.85
Average Volume 2,016,603
200-Day Moving Average 14.44
50-Day Moving Average 22.03
20-Day Moving Average 22.96
10-Day Moving Average 22.94
Average True Range 1.50
ADX 19.97
+DI 19.48
-DI 14.49
Chandelier Exit (Long, 3 ATRs ) 20.51
Chandelier Exit (Short, 3 ATRs ) 26.49
Upper Bollinger Band 23.69
Lower Bollinger Band 22.23
Percent B (%b) 0.36
BandWidth 6.40
MACD Line 0.18
MACD Signal Line 0.33
MACD Histogram -0.1544
Fundamentals Value
Market Cap 185.46 Million
Num Shares 815 Million
EPS -1.50
Price-to-Earnings (P/E) Ratio -15.17
Price-to-Sales 0.00
Price-to-Book 12.26
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.25
Resistance 3 (R3) 24.17 23.58 24.00
Resistance 2 (R2) 23.58 23.20 23.63 23.92
Resistance 1 (R1) 23.17 22.97 22.88 23.25 23.83
Pivot Point 22.58 22.58 22.44 22.63 22.58
Support 1 (S1) 22.17 22.20 21.88 22.25 21.67
Support 2 (S2) 21.58 21.97 21.63 21.58
Support 3 (S3) 21.17 21.58 21.50
Support 4 (S4) 21.25